Constant and steady transgene expression of interferon-γ by optimization of plasmid construct for safe and effective interferon-γ gene therapy

Journal of Gene Medicine

Volumn 14, Issue 4, 2012, Pages 288-295

  Ando, Mitsuru ^a   Takahashi, Yuki ^a   Nishikawa, Makiya ^a   Watanabe, Yoshihiko ^a   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Expression profile; Hydrodynamic injection; Interferon; Plasmid DNA; Proinflammatory cytokine; Promoter

Indexed keywords

DNA; GAMMA INTERFERON; PLASMID VECTOR;

ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE SEQUENCE; GENE THERAPY; GENE TRANSFER; HYDRODYNAMICS BASED TRANSFECTION; IN VIVO GENE TRANSFER; MALE; MEASUREMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; REACTION OPTIMIZATION; WEIGHT CHANGE; WEIGHT REDUCTION;

ANIMALS; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED ICR; PLASMIDS; PROMOTER REGIONS, GENETIC; TRANSGENES;

MURID HERPESVIRUS 1; MURINAE; MUS;

EID: 84859874160     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2616     Document Type: Article

References (25)

1. Grassegger A, Höpfl R. Significance of the cytokine interferon gamma in clinical dermatology. Clin Exp Dermatol 2004; 29: 584-588.
2. Dumortier J, Schönig K, Oberwinkler H, et al. Liver-specific expression of interferon γ following adenoviral gene transfer controls hepatitis B virus replication in mice. Gene Ther 2005; 12: 668-677.
3. Frese M, Schwärzle V, Barth K, et al. Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002; 35: 694-703.
4. Soza A, Heller T, Ghany M, et al. Pilot study of interferon gamma for chronic hepatitis C. J Hepatol 2005; 43: 67-71.
5. Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 2002; 99: 13825-13830.
6. Ellis CN, Stevens SR, Blok BK, Taylor RS, Cooper KD. Interferon-γ therapy reduces blood leukocyte levels in patients with atopic dermatitis: correlation with clinical improvement. Clin Immunol 1999; 92: 49-55.
7. Jang IG, Yang JK, Lee HJ, et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 2000; 42: 1033-1040.
8. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD. Long-term effectiveness and safety of recombinant human interferon-gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998; 134: 799-804.
9. Noh GW, Lee KY. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Allergy 1998; 53: 1202-1207.
10. Foon KA, Sherwin SA, Abrams PG, et al. A phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immunother 1985; 20: 193-197.
11. Mitsui M, Nishikawa M, Zang L, et al. Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. J Gene Med 2009; 11: 435-443.
12. Hattori K, Nishikawa M, Watcharanurak K, et al. Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. J Immunol 2010; 184: 2729-2735.
13. Kawano H, Nishikawa M, Mitsui M, et al. Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA. Int J Cancer 2007; 121: 401-406.
14. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008; 26: 549-551.
15. Brooks AR, Harkins RN, Wang P, Qian HS, Liu P, Rubanyi GM. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 2004; 6: 395-404.
16. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4: 234-43.
17. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-1266.
18. Kobayashi N, Nishikawa M, Hirata K, Takakura Y. Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery. J Gene Med 2004; 6: 584-592.
19. Sebestyén MG, Budker VG, Budker T, et al. Mechanism of plasmid delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of various molecules. J Gene Med 2006; 8: 852-873.
20. Budker VG, Subbotin VM, Budker T, Sebestyén MG, Zhang G, Wolff JA. Mechanism of plasmid delivery by hydrodynamic tail vein injection. II. Morphological studies. J Gene Med 2006; 8: 874-888.
21. Nishikawa M, Nakayama A, Takahashi Y, Fukuhara Y, Takakura Y. Reactivation of silenced transgene expression in mouse liver by rapid, large-volume injection of isotonic solution. Hum Gene Ther 2008; 19: 1009-1020.
22. Zambrowicz BP, Imamoto A, Fiering S, Herzenberg LA, Kerr WG, Soriano P. Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. Proc Natl Acad Sci USA 1997; 94: 3789-94.
23. Liu BH, Wang X, Ma YX, Wang S. CMV enhancer/human PDGF-β promoter for neuron-specific transgene expression. Gene Ther 2004; 11: 52-60.
24. Chen ZY, Riu E, He CY, Xu H, Kay MA. Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther 2008; 16: 548-556.
25. Schüttrumpf J, Milanov P, Abriss D, Roth S, Tonn T, Seifried E. Transgene loss and changes in the promoter methylation status as determinants for expression duration in nonviral gene transfer for factor IX. Hum Gene Ther 2011; 22: 101-106.